Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome by Boyadzhiev M et al.
CASE REPORT Open Access
Disease course and treatment effects of a
JAK inhibitor in a patient with CANDLE
syndrome
M. Boyadzhiev1* , L. Marinov1, V. Boyadzhiev1, V. Iotova1, I. Aksentijevich2 and S. Hambleton3
Abstract
Background: CANDLE syndrome (an acronym for Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and
Elevated Temperature) is a recently described rare autosomal recessive disorder charaterized by systemic
autoinflammation. Clinical manifestations include presentation in the first year of life, episodes of fever
accompanied by erythematous skin lesions, progressive lipodystrophy, violaceous periorbital swelling and failure to
thrive. This syndrome is caused by loss of function mutations and malfunction of the immunoproteasome complex.
Most patients have biallelic mutations in the PSMB8 gene that encodes the β5i catalytic subunit of the
immunoproteasome. Examples of digenic inheritance have been also described in CANDLE. CANDLE patients have
strong type I interferon gene expression signature and they are responsive to treatment with JAK inhibitors.
However, possible serious side-effects remain a concern. Here, we report another patient with CANDLE whose
disease activity was well controlled by the treatment with baricitinib.
Case presentation: We report a Bulgarian patient of the Turkish ancestry who carries biallelic mutations in the
PSMB8 gene: p.Ala92Val and p.Lys105Gln. The pathogenic variant p.Ala92Val has not been previously described in
patients with CANDLE. We also comment on the unusual feature in this patient, nephrolithiasis, that has not been
described in other patients, however it might be related to the positive family history for kidney stones. We have
treated the patient with the JAK inhibitor baricitinib for the past year and we observed a significant amelioration of
his inflammatory episodes, skin and joint manifestations, and improvements in physical activities and growth. The
treatment with glucocorticoids (GC) was completely discontinued. No side effects have been observed, however
they remain in consideration for a life-long therapy of this disease.
Conclusions: CANDLE should be suspected in patients with early-onset systemic inflammatory disease and
prominent skin manifestations. Molecular testing can confirm the clinical diagnosis and is very important in guiding
therapies. Treatment with JAK inhibitors is highly efficacious and appears to be safe in children with CANDLE and
other intereforonopathies.
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Background
Chronic atypical neutrophilic dermatosis with lipodystro-
phy and elevated temperature (CANDLE) syndrome has
been described by Torello et al. in 2010 [1]. CANDLE
syndrome patients present in early-infancy, often during
the neonatal period, with symptoms of recurrent fevers
and a prominent skin rash [1, 2]. The rash tends to be
exacerbated during inflammatory episodes. Torello et al.
described 4 children between 2 and 14 years of age, pre-
senting with annular purpuric plaques mainly on the body.
The authors made a thorough investigation of the skin
lesions through repeated skin biopsies [3]. The periorbital
swelling also appears during the first months of life.
Growth retardation and failure to thrive are some of the
most striking features of the syndrome.
The loss of fat tissue (lipodystrophy) mostly in the
upper limbs and face becomes visible later in the disease
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progress. The lack of fat tissue over the cheeks gives
patients a typical “aging” look. The abdominal fat tissue,
on the contrary, tends to be increased, which leads to
metabolic disturbances [2].
Arthralgia and arthritis are almost always present
although with variable degrees [4]. Myalgia, myositis and
muscle wasting also can lead to reduced patients‘mobi-
lity. Other not so common features are clubbed fingers,
hepatomegaly and splenomegaly, hypertrichosis, acantho-
sis, alopecia areata, arterial hypertension, basal ganglia
calcification [5]. Roberts et al. reported a South African
girl with microdontia and microstomia [6]. The laboratory
findings in patients with CANDLE include increased in-
flammatory markers, CRP, ESR, and marked leukocytosis
[7]. Hypertrigliceridemia is a common finding.
The first disease-causing mutations were identified in
the PSMB8 gene and were associated with functional
dysregulation of the immunoproteasome complex.
Subsequently, mutations in additional genes encoding
both immunoproteasome and constitutive proteasome
subunits were identified: PSMB4, PSMA3, PSMB9. More
recently, heterozygous de novo mutations in the regula-
tory POMP protein have been reported in patients with
autoimmunity, immunodeficiency and autoinflammation
resembling CANDLE. Thus the inheritance pattern in
CANDLE can be autosomal recessive or in the form of a
de novo mutation.
Two more syndromes with a striking resemblence to
the CANDLE syndrome have been reported -
Nakajo-Nishimura syndrome (NNS) was first reported
in 1939 by Dr. Nakajo [8]. In 1950, Nishimura reported
three more cases with similar features. In 2010, Garg et
al. [9] reported three adult patients with a disease they
named Joint Contractures, Muscle atrophy, microcytic
anemia, and Panniculitis-induced lipodystrophy syn-
drome (JMP). Patients diagnosed with NNS and JMP
carry biallelic either homozygous or compound heterozy-
gous mutations in PSMB8. Currently there is no consen-
sus classification of these three syndromes. Some authors
use the term PRAAS (proteasome-associated autoinflam-
matory syndrome), others - ALDD (autoinflammation,
lipodystrophy, and dermatitis) [10]. The exact prevalence
of CANDLE syndrome is yet unknown.
PRAAS is caused by a dysregulation in the proteasome-
immunoproteasome function [11, 12] Immunoprotea-
somes are found mainly in immune cells. Their structure
is very similar to that of the proteasomes [13–15]. Immu-
noproteasome formation is mainly induced by proinflam-
matory cytokines such as IFNs and in response to
increased demand for protein degradation in cells [16, 17].
The production of IFNs is increased during viral infec-
tions or other types of stress. This leads to increased
protein degradation by the immunoproteasomes. When
they are not working properly, the pathogen-derived
proteins and other damaged proteins accumulate in cells
stimulating the production of IFNs. That forms a vicious
circle leading to persistent inflammatory state. Since
JAK-STAT signalling pathway is activating type 1 and 2
IFNs, it is not surprising that wider and more frequent
use of JAK inhibitors in clinical studies leads to remark-
able results [18–20]. As mentioned above, in the case of
CANDLE syndrome, there is a defect in the immuno-
proteasome function that leads to activation of the IFNs
through the JAK-STAT signaling pathway. The expected
efficacy of JAK inhibitors is due to the action they exert
on that exact pathway. The long-term prognosis remains
unclear because of the recent description and the very
limited treatment experience.
Case presentation
We present a 6 years old boy, presented soon after birth
with erythematous eruption and hemorrhagic blisters
(pernio), initially on the palms. Subsequently the rash
spread over the entire body, accompanied with solitary
subcutaneous nodules and violaceous periorbital swell-
ing. His rash was worse during fever episodes. He was
hospitalized multiple times at a tertiary pediatric unit
with the clinical picture of severe inflammation. No
immunisations were administered after the age of 3
months [21]. Three consecutive skin biopsies were per-
formed from active efflorescences. They showed inflam-
mation with the presence of lymphocytes, neutrophils,
macrophages and mastocytes (CD117+). Some parts
showed leukocytoclasis. Several autoimmune and autoin-
flammatory syndromes were considered in the differen-
tial diagnosis, including Sweet syndrome, Mevalonate
kinase deficiency, CINCA/NOMID and leukocytoclastic
vasculitis.
At the age of 1 year 5 months, he was started on meth-
ylprednisolone 1 mg/kg.d-1 with a reasonable effect on
the rash and fevers. However, all attempts to taper the
dose led to immediate relapse of the symptoms. Succe-
sively, hydroxycloroquine and methotrexate were
attempted as GC sparing agents, but they were soon
withdrawn due to lack of any clinical effect.
The boy presented to us at the age of 2 years and 10
months. He was looking pretty unwell, with elevated daily
temperatures reaching 39.9 °C, persistent skin eruption
with nodules, livid and red papules and macules on the
head, body, upper and lower extremities, palms and soles.
Purple periorbital swelling was also present (Fig. 1).
Hypertrichosis was noted all over the body. Subcutaneous
adipose tissue was significant for lipodystrophy. The arms,
shoulders and face had well demarcated outline of the
muscles, which gave the false impression of increased
muscularity. The parents recalled episodes of joint pain
and swelling of knees and fingers, but there was no object-
ive evidence of contractures or joint space narrowing. The
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face was characteristic for atrophic facial musculature and
absence of buccal fat pads, thus giving him an appearance
of an old-man. He also had hypertelorism and epicanthus.
Other symptoms were cough, tachydyspnea and hepato-
megaly. The patient appeared very stunted for his age
group. Age- and sex-specific growth evaluation showed
significant short stature (− 4.1 SDS) and a decreased
weight (− 2.3 SDS), www.cdc.gov/growthcharts. His bone
age, according to Greulich and Pyle’s atlas, was 1 year 3
months (<− 2.0 SDS). Blood workup showed elevated CRP
- 114.09mg/L (0–5.0), neutrophilia, anemia with serum
iron level < 2 mcmol/L (7.2–21.5). Thorough investigation
showed no cardiac, pulmonary or neurologic involvment
at the time.
CANDLE syndrome was suggested as the most prob-
able diagnosis after discussion and evaluation of the pa-
tient’s medical history and current status. Blood samples
from the child and both parents were sent to NIH for
genetic testing. The patient was found to have compound
heterozygous mutations in the PSMB8 gene (p.A92V/
p.K105Q). Both parents are carriers of one mutation.
Follow-up
After confirming the diagnosis of CANDLE, we intended
to find a way to start therapy with JAK inhibitors. At the
age of 3 years 6 months the boy presented with a violent
flank pain. Ultrasound examination showed nephro-
lithiasis, with several small concrements in both kidneys.
His mother reported a history of nephrolithiasis. Two
months later, an abdominal ultrasound revealed mild
hydronephrosis, without any sign of nephrolithiasis. This
finding remains until the present time.
Other complications have appeared with time, related
to the syndrome and the therapies. At 5 years of age des-
pite the high doses of glucocorticoids, inflammatory
flares with fever, and elevated CRP continued to be
Fig. 1 The patient: a. When he is 2 years 10 months old; b. When he is 5 years old, just before the start of baricitinib; c. After 7 months of
treatment with baricitinib
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frequent – at least one episode every month. Failure to
thrive was progressing. Arterial hypertension with the
blood pressure reaching 160/100 mmHg and frequent
headaches necessitated addition of ACE-inhibitor and
calcium inhibitor to his therapy. Cholesterol was high
for age (5.97 mmol/l).
Gastric complaints became frequent with stomach
pain and vomiting at least once weekly. While on high
doses of methylprednisolone his appetite became
voracious. Despite the large food intake his height
remained static, while growth velocity was less than 0.5
cm per year (Fig. 1). The patient complained of muscle
pain, difficulty walking and easy fatigue.
The JAK 1/2 inhibitor baricitinib (Olumiant) was
started shortly after the patient‘s 5th birthday. The NIH
protocol was followed with a starting dose of 6 mg/day
for the first 3 days, and after no side effects were
observed the dose was increased to 8mg/day. After 7
months of treatment we witnessed dramatic and object-
ive improvements:
 No new episodes of systemic inflammation for the
past 3 months: no fevers, malaise, and vomiting.
 The first attempt of stopping glucocorticoid
treatment completely was undertaken 3 months
after the start of baricitinib. The GC dose was
quickly tapered down from 1 mg/kg/day to less than
0.1 mg/kg/day during the first month. This led to
the new appearance of three violaceous
subcutaneous nodules, resembling the typical rash
for CANDLE on his foot and fingers), which
disappeared in a week. Methylprednisolone
treatment was completely stopped at 5th month
after the initiation of treatment with baricitinib and
without further relapses.
 Drastic improvement of the skin rash, and
dissapearence of the periorbital swelling (Fig. 1)
 Normalisation of the blood pressure, allowing the
withdrawal of the calcium inhibitor during the
second month of treatment and the ACE-inhibitor
after 7 months.
 Increased growth velocity - +8.8 cm/7 months,
extrapolated growth velocity of 15 cm/year.
 Decreased abdominal circumference by 8 cm - from
65 cm to 57 cm.
 Improved mobility with no complaints of fatigue
and/or muscle pain. Soon after the start of
baricitinib treatment the patient was able to perform
longer and more difficult physical activities.
 During 7 months of treatment the patient needed a
5 day-treatment with an antibiotic due to a common
upper airways infection.
Shortly after the start of baricitinib the boy refused to
walk, and complained of muscle pain in the thighs. No
clinical or laboratory signs of myositis or arthritis were
found. Complaints continued for a week, without wors-
ening or further complications.
During the patient‘s visit on the seventh month after the
start of baricitinib treatment he was feeling much better,
with no pain while walking in contrast to his previous
visits, with normalized appetite and increased physical en-
durance. Control blood count showed normal leucocytes
and hemoglobin, and normal neutrophil count. Despite
the lack of clinical symptoms, elevated CRP values were
noted on two occasions, raising the question of the best
dose of baricitinib (Table 1). The significant increase in his
growth velocity has been documented (Fig. 2). Those
findings repeated during the visit at the end of the first
year after the start of baricitinib treatment (Fig. 2).
Discussion
We present a young patient with molecularly confirmed
CANDLE syndrome. The patient is compound
Table 1 Inflammation markers during the patient follow up
Date Age Leucocytes ×109/L Neutrophils ×109/L CRP mg/L
June 2015 2 y 10 mo 8.27 7.51 114.09
April 2016 3 y 8 mo 16.62 11.01 23.71
November 2016 4 y 3 mo 16.12 12.16 16.3
January 2017 4 y 5 mo 10.81 9.11 76.18
March 2017 4 y 7 mo 10.89 5.12 43.04
Start of Baricitinib in August 2017
September 2017 5 y 0 mo 16.88 12.24 2.8
October 2017 5 y 2 mo 8.73 3.5 0.13
December 2017 5 y 4 mo 7.66 3.53 8.78
February 2018 5 y 5 mo 7.89 4.47 17.13
April 2018 5 y 7 mo 6.74 2.78 7.48
February 2019 6 y 5 mo 7.5 5.79 18.63
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heterozygous: he has two mutations in the PSMB8 gene
(p.A92V/p.K105Q). One of the mutations – p.Ala92Val
(c.275C > T) is novel and has not been reported, al-
though another mutation affecting the same amino acid
residue is reported in patients with CANDLE [22]. The
second mutation p.Lys105Gln (c.313A > C; p.K105Q)
was recently described in a report from Brehm et al. in
2015 [16].
The patient was treated with JAK 1/2 inhibitor, barici-
tinib, for a period of 1 year and 6months without any
side effects and with impressive improvement in all
aspects of the disease.
JAK inhibitors are part of a new class of small mol-
ecule drugs and they have been used in the treatment
of rare oncologic diseases and many autoimmune and
autoinflammatory diseases. Janus Kinase inhibition has
been used with a different degree of success in myelo-
proliferative diseases, lupus, psoriatic arthritis, inflam-
matory bowel diseases [23, 24]. They are especially
efficient in the treatment of adult rheumatoid arthritis,
Fig. 2 Growth chart of the patient
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showing promising results in comparison with bio-
logical agents. JAK inhibitors are also very convenient
for the patients because of their oral intake.
Treatment effect of baricitinib described in this article
is comparable to the previous published reports in
CANDLE patients [18]. The mean dose of baricitinib
in this study was 8.5 mg/day. Our patient is on a
maintenance dose of 8 mg/day. However, increased
values of CRP in our patient were detected during
the last couple of visits. No other signs of infections
were present. This indicates the presence of persisting
subclinical inflammation and raises the question about
the best dose of baricitinib.
Montealegre et al. described a decrease in the mean
glucocorticoid dose by 73%, and 4 out of 12 patients
managed to discontinue glucocorticoids completely.
After 5 months of treatment in our patient, the GC
treatment was discontinued completely and with no
disease relapses.
Five out of six patients with myositis, described by the
above referenced study, showed improvement in muscle
fatigue and improved physical endurance as it has been
the case with our patient [18]. Joint involvement, which
is a typical clinical finding for most of the published
CANDLE patients, was not a predominating feature in
our case.
The study by Montealegre et al. also described 17
serious adverse events in 4 patients. Most common were
those of infectious origin – infections of the upper
respiratory tract, one probable Pneumocystis jiroveci
pneumonia, Rotavirus and Clostridium difficile infec-
tions. One patient has been removed from the study due
to a lack of efficacy and development of avascular necro-
sis. Our patient did not suffer from any serious compli-
cations connected to an infectious cause or any other
adverse events.
Our patient showed persistently normal hemoglobin
levels during the treatment, while two patients reported
by Montealegre et al. developed anemia.
The results from the JAK inhibitor treatment of here de-
scribed patient with CANDLE syndrome are consistent
with the previously published cohort study, with catch-up
growth and physical activity improving significantly more
in our patient. The short-term effects of JAK 1/2 inhibitor
according to our expirience are excellent with no side
effects reported, though the long-term effectiveness and
possible serious side-effects remain a concern. The
increased values of CRP, suggesting persistent subclinical
inflammation, raise the question if the best dose of barici-
tinib is 8mg/day or higher. Tofacitinib has been used by
other authors with beneficial effect [25] but we do not
have experience with the drug.
Although glucocorticoids control the acute inflamma-
tion, the significant side effects make their long term use
undesirable. We hope that JAK inhibitors will secure a
long-term control of the disease symptoms without severe
side-effects and a better quality of life of the children
affected by CANDLE syndrome.
Conclusion
The results from the JAK inhibitor treatment of here de-
scribed patient with CANDLE syndrome are consistent
with the previously published cohort study. Although
the short-term effects of JAK 1/2 inhibitor are excellent,
the long-term effectiveness and possible serious sideef-
fects remain a concern.
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